BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38740983)

  • 21. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization.
    Jin YJ; Chung YH; Kim JA; Park W; Lee D; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Kim PN; Sung KB
    Dig Dis Sci; 2013 Jun; 58(6):1758-65. PubMed ID: 23361574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Oshita M; Ohkawa K; Kodama T; Hikita H; Tatsumi T; Takehara T
    Hepatol Res; 2020 Nov; 50(11):1275-1283. PubMed ID: 32812315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy.
    Poon RT; Fan ST; O'Suilleabhain CB; Wong J
    J Am Coll Surg; 2002 Sep; 195(3):311-8. PubMed ID: 12229937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.
    Jang ES; Yoon JH; Chung JW; Cho EJ; Yu SJ; Lee JH; Kim YJ; Lee HS; Kim CY
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):635-43. PubMed ID: 23283527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
    Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
    Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation.
    Cheng YC; Chen TW; Fan HL; Yu CY; Chang HC; Hsieh CB
    Ann Transplant; 2014 Jun; 19():309-16. PubMed ID: 24975583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation.
    Terzi E; Ray Kim W; Sanchez W; Charlton MR; Schmeltzer P; Gores GJ; Andrews JC; Smyrk TC; Heimbach JK
    Liver Transpl; 2015 Feb; 21(2):248-57. PubMed ID: 25371111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Kim SS; Cho HJ; Nam JS; Kim HJ; Kang DR; Won JH; Kim J; Kim JK; Lee JH; Kim BH; Lee MY; Cho SW; Cheong JY
    J Korean Med Sci; 2018 Jan; 33(1):e6. PubMed ID: 29215815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
    Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
    Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
    Kuo MJ; Mo LR; Chen CL
    BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.
    Kinugasa H; Nouso K; Takeuchi Y; Yasunaka T; Onishi H; Nakamura S; Shiraha H; Kuwaki K; Hagihara H; Ikeda F; Miyake Y; Takaki A; Yamamoto K
    J Gastroenterol; 2012 Apr; 47(4):421-6. PubMed ID: 22048256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study.
    Lee HS; Kim KM; Yoon JH; Lee TR; Suh KS; Lee KU; Chung JW; Park JH; Kim CY
    J Clin Oncol; 2002 Nov; 20(22):4459-65. PubMed ID: 12431969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
    Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.